BRMU8602999U - medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares - Google Patents
medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovascularesInfo
- Publication number
- BRMU8602999U BRMU8602999U BRMU8602999-1U BRMU8602999U BRMU8602999U BR MU8602999 U BRMU8602999 U BR MU8602999U BR MU8602999 U BRMU8602999 U BR MU8602999U BR MU8602999 U BRMU8602999 U BR MU8602999U
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- rosuvastatin
- cardiovascular diseases
- metformine
- hypertension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Abstract
O MEDICAMENTO "ROSUVASTATINA + METFORMINA EM FORMA COMBINADA PARA DOENçAS CARDIOVASCULARES, resuma-se a combinação de dois medicamentos utilizados contra as doenças cardiovasculares são a principal causa de morte em nosso país. Há nítida correlação entre o ganho ponderal e o excesso de peso com risco de doenças cardiovasculares. O excesso de peso predispõe a estas doenças devido anormalidades no metabolismo dos lípides, glicose e pressão arterial. A resistência à insulina / hiperinsulinemia parece ser um fator de risco independente de outros fatores de risco associados, como a obesidade, hiperlipidemia e hipertensão, tanto em homens como em mulheres. A insulina e os fatores de crescimento semelhantes à insulina estimulam a atividade das células musculares lisas e estão envolvidas na aterogênese e mesmo na reestenose que se segue ao repara coronário pela angioplastia. Outros efeitos da insulina estão relacionados aos mecanismos que contribuem para o desenvolvimento tanto da hipertensão como da dislipidemia. O MEDICAMENTO "ROSUVASTATINA + METFORMINA" EM FORMA COMBINADA PARA DOENCAS CARDIOVASCULARES, diminuindo a resistência insulínica, a pressão arterial, o ganho ponderal e melhorando o perfil lipídico destes paciente, reduziriam muito a probabilidade de eventos cardiovasculares e conseqüentemente o óbito dessa natureza em nossa população.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRMU8602999-1U BRMU8602999U (pt) | 2006-11-16 | 2006-11-16 | medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares |
PCT/BR2007/000349 WO2008058358A2 (en) | 2006-11-16 | 2007-11-14 | Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRMU8602999-1U BRMU8602999U (pt) | 2006-11-16 | 2006-11-16 | medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares |
Publications (1)
Publication Number | Publication Date |
---|---|
BRMU8602999U true BRMU8602999U (pt) | 2008-07-08 |
Family
ID=39402026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRMU8602999-1U BRMU8602999U (pt) | 2006-11-16 | 2006-11-16 | medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares |
Country Status (2)
Country | Link |
---|---|
BR (1) | BRMU8602999U (pt) |
WO (1) | WO2008058358A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
KR20140035331A (ko) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 화학감각 수용체 리간드-기반 요법 |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
JP6175074B2 (ja) | 2012-01-06 | 2017-08-02 | エルセリクス セラピューティクス インコーポレイテッド | 代謝障害を治療するための組成物および方法 |
JP2015522080A (ja) * | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171407A1 (en) * | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
-
2006
- 2006-11-16 BR BRMU8602999-1U patent/BRMU8602999U/pt not_active IP Right Cessation
-
2007
- 2007-11-14 WO PCT/BR2007/000349 patent/WO2008058358A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008058358A3 (en) | 2009-04-16 |
WO2008058358A2 (en) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRMU8602999U (pt) | medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares | |
Young et al. | Milrinone: a preliminary review of its pharmacological properties and therapeutic use | |
Toklu et al. | Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats | |
da Luz et al. | Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats | |
Baltaci et al. | Resveratrol and exercise | |
Sekar et al. | Antidiabetic effect of mangiferin in combination with oral hypoglycemic agents metformin and gliclazide | |
Koyasu et al. | Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease | |
Hennekens et al. | Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions | |
CN102958362A (zh) | 含有白藜芦醇的组合物和应用方法 | |
Smirin et al. | Sarcopoterium spinosum extract as an antidiabetic agent: in vitro and in vivo study | |
Bampi et al. | Depression-like behavior, hyperglycemia, oxidative stress, and neuroinflammation presented in diabetic mice are reversed by the administration of 1-methyl-3-(phenylselanyl)-1H-indole | |
PT1680112E (pt) | N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina | |
CY1116303T1 (el) | Παραγωγο ακυλβενζολιου | |
US20160346340A1 (en) | Compositions including milk thistle and methods for the treatment of various disorders using the same | |
BRMU8602970U (pt) | medicamento "telmisartam + metformina" em forma combinada para doenças cardiovasculares | |
BRMU8602979U (pt) | medicamento "atorvastatina + metformina" em forma combinada para doenças cardiovasculares | |
BRMU8602991U (pt) | medicamento "candesartana + metformina" em forma combinada para doenças cardiovasculares | |
BRMU8602968U (pt) | medicamento "ramipril + metformina" em forma combinada para doenças cardiovasculares | |
BRMU8403417U (pt) | medicamento sinvastatina + metformina em forma combinada para doenças cardiovasculares | |
Nettelblad et al. | Psoralens used for cosmetic sun tanning: an unusual cause of extensive burn injury | |
BRMU8403463U (pt) | medicamento combinado amlodipino + metformina em forma combinada para doenças cardiovasculares | |
BRMU8403462U (pt) | medicamento valsartan + metformina em forma combinada para doenças cardiovasculares | |
Hiyama et al. | Effects of metformin on burn-induced hepatic endoplasmic reticulum stress in male rats | |
Graham et al. | Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDs | |
BRMU8403482U (pt) | "enalapril+metformina" em forma combinada para doenças cardiovasculares |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B03A | Publication of an application: publication of a patent application or of a certificate of addition of invention | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012. |